Enveric Biosciences, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Joseph Edward Tucker
- Full Time Employees
- 6
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 245 First Street Cambridge MA United States of America 02142
- IPO Date
- May 4, 2015
- CIK
- 0000890821
- Website
- enveric.com
- Similar Companies
- Business
- Enveric Biosciences, Inc. (NASDAQ: ENVB) develops novel neuroplastogenic small-molecule therapeutics targeting depression, anxiety, addiction disorders, and other neuropsychiatric conditions; its Psybrary discovery platform generates proprietary psychedelic-inspired molecules designed to promote neuroplasticity without hallucinogenic effects; lead candidate EB-003 advances in preclinical development as a potential first-in-class neuroplastogen for severe mental health disorders, with plans for first-in-human trials in 2026; the EVM401 series of mescaline derivative compounds expands the pipeline for addiction, neuropsychiatric, neurodegenerative, and cognitive applications; additional Psybrary-derived candidates, including EVM301 and EVM201 series, support out-licensing opportunities. The company out-licenses non-core assets, including the EVM201 program featuring EB-002 to MycoMedica Life Sciences for up to $62 million in milestones plus royalties, and patented Cannabinoid-COX-2 conjugate compounds to Restoration Biologics for joint disease treatment with potential milestones up to significant values; recent financing includes $2.2 million from warrant exercises to fund EB-003 development and IP expansion; new U.S. patents cover EVM301, EB-003, and EVM401 series; in September 2025, Enveric relocated its corporate headquarters from Naples, Florida, to Cambridge, Massachusetts, to access biotech talent, collaborations, and capital in the Greater Boston hub while maintaining offices in Calgary, Canada. Founded through a 2020 reverse merger and operating from Calgary, Alberta, Canada origins, Enveric targets patients with unmet needs in mental health via U.S.-based development and global licensing partnerships.
Company News
Enveric Biosciences to Present at H.C. Wainwright 28th Annual Global Investment Conference
Enveric Biosciences Reports Financial Results and Provides Corporate Update for Second Quarter 2026
Enveric Biosciences Says New Preclinical Data Confirms Non-Hallucinogenic Profile For Lead Psychiatric Candidate
Enveric Biosciences Reports New Preclinical Data Supporting the Non-Hallucinogenic Profile of Lead Candidate EB-003
Enveric Biosciences Welcomes Final FDA Guidance for Psychedelic Drug Development
Enveric Biosciences Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit
Enveric Biosciences Announces Participation in 2026 BIO International Convention
Enveric Biosciences Announces Participation in 2026 BIO International Convention
Enveric Biosciences to Participate in the UBS 3rd Virtual CNS Day
Enveric Biosciences Initiates Investigational New Drug (IND)-enabling Genotoxicity Studies of Lead Neuroplastogen Candidate EB-003
Enveric Biosciences Reports Positive Preclinical Results from Phototoxicity Analysis for Lead Neuroplastogen Candidate EB-003
Enveric Biosciences Reports Financial Results and Provides Corporate Update for First Quarter 2026
Enveric Biosciences Reports Financial Results and Provides Corporate Update for First Quarter 2026
Enveric Biosciences Expands IP Portfolio with New U.S. Patent Issued for Methods of Treating Psychiatric Disorders
Enveric Biosciences Highlights Positive Results for EB-003 in PTSD Preclinical Model
Lakewood-Amedex Biotherapeutics Appoints Joseph Tucker, Ph.D., to Board of Directors
What's Going On With Enveric Biosciences Stock On Friday?
Enveric Biosciences to Participate in a Panel Discussion at Needham's Virtual Psychedelics Forum
Enveric Biosciences Stock Soars After Trump's Psychedelics Executive Order
Enveric Biosciences Announces Closing of Up To $13.9 Million Private Placement Priced At-The-Market Under Nasdaq Rules